The spasticity-related quality of life 6-dimensions instrument in upper-limb spasticity: Part I Development and responsiveness

TY - JOUR

T1 - The spasticity-related quality of life 6-dimensions instrument in upper-limb spasticity:

T2 - Part I Development and responsiveness

AU - Turner-Stokes, Lynne

AU - Fheodoroff, Klemens

AU - Jacinto, Jorge

AU - Lambert, Jeremy

AU - De La Loge, Christine

AU - Calvi-Gries, Françoise

AU - Whalen, John

AU - Lysandropoulos, Andreas

AU - Maisonobe, Pascal

AU - Ashford, Stephen

PY - 2022/1/3

Y1 - 2022/1/3

N2 - OBJECTIVE: To describe the development of the Spasticity-related Quality of Life 6-Dimensions instrument (SQoL-6D) and its sensitivity to clinical change (responsiveness).DESIGN: Multicentre, prospective, longitudinal cohort study at 8 UK sites (NCT03442660).PATIENTS: Adults (n = 104) undergoing focal treatment of upper limb spasticity.METHODS: No condition-specific health-related quality of life tool is available for upper-limb spasticity of any aetiology. The SQoL-6D was developed to fulfil this need, designed to complement the Upper Limb Spasticity Index (which incorporates the Goal Attainment Scaling evaluation of upper limb spasticity [GASeous] tool) with targeted standardized measures. The 6 dimensions of the SQoL-6D (score range 0-4) map onto common treatment goal areas identified in upper-limb spasticity studies. A Total score (0-100) provides overall spasticity-related health status. To assess responsiveness, the SQoL-6D, Global Assessment of Benefit scale and "GASeous" were administered at enrolment and 8 weeks.RESULTS: Significant differences in mean SQoL-6D Total score change and effect sizes across patients rating "some benefit" (0.51) and "great benefit" (0.88) supported responsiveness.CONCLUSION: The SQoL-6D is a promising new measure of health status in upper limb spasticity, that enables systematic assessment of the impact of this condition in relation to patients' priority treatment goals. A psychometric evaluation of SQoL-6D is presented separately.

AB - OBJECTIVE: To describe the development of the Spasticity-related Quality of Life 6-Dimensions instrument (SQoL-6D) and its sensitivity to clinical change (responsiveness).DESIGN: Multicentre, prospective, longitudinal cohort study at 8 UK sites (NCT03442660).PATIENTS: Adults (n = 104) undergoing focal treatment of upper limb spasticity.METHODS: No condition-specific health-related quality of life tool is available for upper-limb spasticity of any aetiology. The SQoL-6D was developed to fulfil this need, designed to complement the Upper Limb Spasticity Index (which incorporates the Goal Attainment Scaling evaluation of upper limb spasticity [GASeous] tool) with targeted standardized measures. The 6 dimensions of the SQoL-6D (score range 0-4) map onto common treatment goal areas identified in upper-limb spasticity studies. A Total score (0-100) provides overall spasticity-related health status. To assess responsiveness, the SQoL-6D, Global Assessment of Benefit scale and "GASeous" were administered at enrolment and 8 weeks.RESULTS: Significant differences in mean SQoL-6D Total score change and effect sizes across patients rating "some benefit" (0.51) and "great benefit" (0.88) supported responsiveness.CONCLUSION: The SQoL-6D is a promising new measure of health status in upper limb spasticity, that enables systematic assessment of the impact of this condition in relation to patients' priority treatment goals. A psychometric evaluation of SQoL-6D is presented separately.

U2 - 10.2340/jrm.v53.690

DO - 10.2340/jrm.v53.690

M3 - Article

C2 - 34726763

SN - 1650-1977

VL - 54

JO - JOURNAL OF REHABILITATION MEDICINE

JF - JOURNAL OF REHABILITATION MEDICINE

ER -